Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2019

Note 7 - Accounts Payable and Accrued Expenses

At March 31, 2019 and December 31, 2018, accounts payable and accrued expenses consisted of the following ($ in thousands):

	March 31,		December 31,
	2019		2018
Accounts payable	$	4,448	$	9,750
Accrued compensation		111		439
Research and development		2,488		1,751
Other		360		377
Accounts payable and accrued expenses - related party		803		776
Total accounts payable and accrued expenses	$	8,210	$	13,093